scholarly journals Folate intake, alcohol consumption, and the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism: influence on prostate cancer risk and interactions

Author(s):  
Lindsay C. Kobayashi
2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Lionel L. Bañez ◽  
Cathrine Hoyo ◽  
Elizabeth M. Masko ◽  
Elizabeth E. Calloway ◽  
Kathleen H. Shuler ◽  
...  

2018 ◽  
Vol 13 (1) ◽  
pp. 98
Author(s):  
Qunshan Shen ◽  
Yu Liang ◽  
Haibo Li ◽  
Mei Chen ◽  
Jun Zhang ◽  
...  

<p class="Abstract">The aim of this meta-analysis was to assess the association between SLCO1B3 gene polymorphism and prostate cancer risk. PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2017 were searched. Three authors independently selected studies, extracted data and assessed risk of bias. 5 articles published from 2008 to 2013 with 840 patients were included in this meta-analysis and were from Japan, USA and China. The prostate cancer risk of SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG, RR= 0.44, 95%CI: 0.39-0.49, p&lt;0.00001), rs4149117 (TT, RR= 0.37, 95%CI: 0.32-0.42, p&lt;0.00001) and rs4149117 (TG, RR= 0.07, 95%CI: 0.05-0.10, p&lt;0.00001). 2 or 5 years risk  free symptoms (RFS) of prostate cancer patient with SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG) (RR= -0.17, 95% CI: -0.27--0.07, p= 0.001 and RR= -0.08, 95% CI: -0.16-0.00, p= 0.004). However, no evidence showed there existed significant statistical relationship between SLCO1B3 (rs4149117) and 10 years RFS of prostate cancer (RR= -0.07, 95% CI: -0.19-0.06, p= 0.29). These data suggest that SLCO1B3 (rs4149117, GG) enhanced the RFS of prostate cancer.</p>


2012 ◽  
Vol 132 (9) ◽  
pp. 2176-2185 ◽  
Author(s):  
Luisa Zuccolo ◽  
Sarah J. Lewis ◽  
Jenny L. Donovan ◽  
Freddie C. Hamdy ◽  
David E. Neal ◽  
...  

2013 ◽  
Vol 27 (3) ◽  
pp. 213-218 ◽  
Author(s):  
Ayşe Eken ◽  
Onur Erdem ◽  
Zorica Arsova-Sarafinovska ◽  
Cemal Akay ◽  
Ahmet Sayal ◽  
...  

The Prostate ◽  
2002 ◽  
Vol 51 (1) ◽  
pp. 30-34 ◽  
Author(s):  
Andrea Gsur ◽  
Stephan Madersbacher ◽  
Gerald Haidinger ◽  
Georg Schatzl ◽  
Michael Marberger ◽  
...  

2011 ◽  
Vol 10 (9) ◽  
pp. 615
Author(s):  
S. Mahmood ◽  
M. Kmet'ova-Sivoòova ◽  
D. Dobrota ◽  
S. Grobarèiková ◽  
J. Kliment

Author(s):  
Samah Tellouche-bouhouhou ◽  
Djalila Chellat-rezgoune ◽  
Noureddine Abadi ◽  
Dalila Satta ◽  
Abderrezak Dahdouh

Objective: The single nucleotide polymorphism C677T of the methylenetetrahydrofolate reductase (MTHFR) gene encodes a thermolabile enzyme. This polymorphism was found to be implicated in cancer susceptibility. In this study, we analyzed the distribution of the MTHFR C677T polymorphism in two cohorts; patients and controls native of East of Algeria to explore the possible association between this polymorphism and prostate cancer susceptibility.Methods: Our examination has been conducted in 98 cases and 98 healthy controls. Genotyping was realized by polymerase chain reaction-restriction fragment length polymorphism method.Results: Compared with CC homozygous, the CT heterozygous was found to have a significantly increased risk of prostate cancer (p=0.04; odds ratio [OR]=2.01, 95% confidence interval [CI]: 1.02–3.95). However, no statistically significant difference was observed concerning the TT homozygous (p=0.74; OR=1.25, 95% CI: 0.51–3.04).Conclusion: Our results indicate that the genotype CT is a risk factor for prostate cancer in East of Algeria.


2016 ◽  
Vol 16 (1) ◽  
pp. NP6-NP11 ◽  
Author(s):  
Chao Ou ◽  
Yan Zhao ◽  
Jiang-Hua Liu ◽  
Bo Zhu ◽  
Pei-Zhang Li ◽  
...  

Cancer ◽  
2009 ◽  
Vol 115 (16) ◽  
pp. 3661-3669 ◽  
Author(s):  
Zhihong Gong ◽  
Alan R. Kristal ◽  
Jeannette M. Schenk ◽  
Catherine M. Tangen ◽  
Phyllis J. Goodman ◽  
...  

2008 ◽  
Vol 29 (12) ◽  
pp. 2335-2340 ◽  
Author(s):  
Bahar Mikhak ◽  
David J. Hunter ◽  
Donna Spiegelman ◽  
Elizabeth A. Platz ◽  
Kana Wu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document